Callahan Advisors LLC Makes New $1.09 Million Investment in DaVita Inc. $DVA

Callahan Advisors LLC purchased a new position in DaVita Inc. (NYSE:DVA) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 9,592 shares of the company’s stock, valued at approximately $1,090,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Invesco Ltd. lifted its holdings in shares of DaVita by 2.0% in the 3rd quarter. Invesco Ltd. now owns 1,679,248 shares of the company’s stock worth $223,122,000 after acquiring an additional 32,358 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of DaVita by 8.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,085,593 shares of the company’s stock worth $144,230,000 after acquiring an additional 88,061 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of DaVita by 109.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock worth $73,585,000 after acquiring an additional 289,725 shares during the last quarter. Neuberger Berman Group LLC lifted its holdings in shares of DaVita by 138.5% in the 3rd quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock worth $61,502,000 after acquiring an additional 269,015 shares during the last quarter. Finally, KBC Group NV lifted its holdings in shares of DaVita by 16.3% in the 4th quarter. KBC Group NV now owns 434,211 shares of the company’s stock worth $49,331,000 after acquiring an additional 60,910 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Up 1.1%

NYSE:DVA opened at $196.84 on Thursday. The company has a fifty day moving average of $161.12 and a 200 day moving average of $137.14. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $202.69. The firm has a market capitalization of $12.64 billion, a P/E ratio of 18.26, a P/E/G ratio of 0.64 and a beta of 0.84.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same period in the prior year, the business posted $2.00 EPS. The firm’s revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts anticipate that DaVita Inc. will post 15.07 EPS for the current year.

Insider Buying and Selling

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $126.00 to $220.00 in a report on Wednesday, May 6th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. UBS Group boosted their price objective on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Finally, Barclays upped their price target on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, DaVita presently has an average rating of “Hold” and a consensus price target of $199.17.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.